-
-
-
-
-
-
-
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
-
-
-
-
-
-
-
Axcella Announces Program Reprioritization and Corporate Restructuring
-
-
-
-
-
-
-
Axcella Reports Second Quarter Financial Results and Provides Business Update
-
-
-
-
-
-
-
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
-
-
-
-
-
-
-
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
-
-
-
-
-
-
-
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
-
-
-
-
-
-
-
Axcella Health (AXLA) Announces Positive Clinical Data About AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
-
1,197,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

